Reminder: Roche Virtual Event – Key ophthalmology data presented at the Angiogenesis 2023 Meeting Montag, 06. Februar 2023 - 14:06

Monday 13th February 2023

We are pleased to invite investors and analysts to participate in our virtual event on Monday, 13 February 2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February.

16:30 – 18:00 CET / 15:30 – 17:00 GMT

10:30 – 12:00 pm EST / 7:30 – 9:00 am PST

Agenda

• Welcome - Bruno Eschli, Head of Investor Relations
• Roche ophthalmology strategy - Nilesh Mehta, Global Franchise Head of Ophthalmology
• Roche ophthalmology pipeline - Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development
• Key data presented at Angiogenesis - Veeral S. Sheth, MD, MBA, FASRS, FACS, Retina Specialist and Clinical Investigator

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event.
> click here

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Loren Kalm

Head of Investor Relations, North America

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com